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Abstract 
 
The past two decades have seen the identification of important roles for calcium signalling 
in many of the hallmarks of cancer. One of the cancer types that has been a particular focus 
of such studies is breast cancer. The breast is intrinsically linked to the calcium ion due to 
the importance of milk calcium in neonatal growth and development. Indeed, some of the 
calcium channels and pumps involved in transporting calcium ions into milk also have 
altered expression in some breast cancers. However, altered expression is not confined to 
channels and pumps important in lactation, other calcium channels and pumps may also be 
modulated and may even be specific to breast cancer molecular subtypes. This review 
considers calcium signalling in the context of breast cancer and provides an overview of the 
roles that have been attributed to specific regulators of cellular calcium levels in processes 
relevant to breast cancer progression. Emerging areas in the study of calcium signalling in 
breast cancer are considered, such as the intersection between calcium signalling, the 
tumour microenvironment and breast cancer. 
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1 Introduction 
 
The regulation of proliferation, migration and invasion, and cell death processes by the 
calcium signal and the altered expression of specific components of the calcium signalling 
“toolkit”[1] are being investigated in an increasing number of studies, with some focus on 
assessing the intersection between calcium signalling and different cancer types[2-5]. In this 
review, we will concentrate on calcium signalling in breast cancer. We will also briefly reflect 
on the unique role of calcium fluxes in lactation, the physiological role of the breast. 
 
1.1 Calcium signalling and transport 
 
Many authors have already reviewed and defined the components and complexity of 
calcium signalling e.g.[6-8]. Figure 1 represents a very general overview of some of the 
channels, pumps and exchangers that can transport calcium and thus contribute to levels of 
free calcium ions (Ca2+) in the cytoplasm and intracellular organelles of breast cancer cells. 
This review will focus on some of the studies that have provided evidence in defining the 
role of specific regulators of calcium signalling in breast cancer progression.  
 
1.2 The breast, milk and calcium 
 
Surprising until very recently the specific molecular components responsible for Ca2+ making 
its way from the maternal blood supply into milk were poorly understood. Work published 
in 2004 gave the first indication that the plasma membrane calcium efflux pump Pmca2, 
located on the apical membrane, was responsible for the direct transport of Ca2+ into milk 
from the epithelial cell[9]. Orai1 calcium channels were subsequently identified via 
knockout animal studies as at least one of the mechanisms by which Ca2+ crosses the 
basolateral membrane into mouse mammary epithelial cells[10]. Orai1 knockout animal 
studies also identified an unexpected but critical role for Orai1 in the contraction of 
myoepithelial cells for milk expulsion[10]. Expression of another calcium pump, Spca2, is 
(like Pmca2 and Orai1) also significantly increased with lactation in mice and given its role as 
a Golgi pump, suggestions are that Spca2 is involved in the secretion of Ca2+ into milk[11]. 
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As will be outlined below, all three human analogues of these proteins (PMCA2, ORAI1 and 
SPCA2) are linked to breast cancer in some way. 
 
1.3 Breast cancer 
 
Prognosis and treatment approaches are heavily influenced by the specific subtype of breast 
cancer, as illustrated in Figure 2. Evidence also shows that different breast cancer subtypes 
are associated with changes in the expression of specific calcium channels or pumps. 
 
1.4 Breast cancer subtypes and altered expression of calcium signal regulators 
 
One of the complexities in the area of breast cancer research is the multiple classification 
methods used, which reflects the striking heterogeneity both between and within breast 
tumours in different patients. Clinically, breast cancers may be classified by morphological 
type, histological grade or immunohistochemical subtype (expression of receptors for 
oestrogen, progesterone and epidermal growth factor (ER/PR/HER2)); and for research 
purposes, also according to gene expression profile (e.g. luminal-A, luminal-B, Her2, basal-
like and claudin-low molecular subtypes)[12-16]. Often there is significant overlap between 
these phenotypes[13, 17]; breast cancers classified as ER+ and PR+ are often of the luminal-
A and -B molecular subtypes, the Her2 molecular subtype is mostly HER2+ and triple-
negative breast cancers, which lack expression of ER, PR and HER2, are usually either basal-
like or claudin-low[17]. Figure 2 summarises various breast cancer subtypes and overlapping 
phenotypes.  
 
Despite being a key method in the classification of breast cancers, there are very few studies 
comparing the expression of calcium channels or pumps in different histological types. 
Pursuing this avenue of research is worthwhile, exemplified by studies assessing the calcium 
pump SERCA3 where histological type and various grades were extensively considered[18]. 
In comparison, there are many studies comparing the levels of various calcium channels and 
pumps in breast cancers classified based on immunohistochemical or molecular subtype. 
Some specific examples of these studies are presented below, and in Table 1 we present a 
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more comprehensive summary of breast cancer tissue and breast cancer cell lines where 
there is a change in the expression of specific calcium channels or pumps.  
 
TRPV6 is an ion channel with high Ca2+ selectivity and constitutive activity[19]. It is over-
expressed in a variety of malignancies including those of the prostate and breast[20], and in 
basal-like breast tumours there is a correlation between TRPV6 gene copy-number and RNA 
expression, suggesting high expression is positively selected as a cancer driver in the 
evolution of some cancers[21]. The calcium efflux pump PMCA2 is another gene associated 
with breast cancer heterogeneity, with compelling evidence of a positive association with 
HER2 expression in human ductal carcinoma in situ, as shown by gene array and 
immunofluorescence studies[22]. A further example is the mitochondrial calcium uniporter 
(MCU), expressed significantly higher in ER-negative compared to ER-positive tumours, 
particularly those with a basal-like phenotype[23]. Interestingly, MCU, a critical regulator of 
mitochondrial Ca2+ levels, is positively correlated with hypoxia inducible factor (HIF) 1A as 
well as a pre-defined set of HIF‐1α‐regulated genes in breast cancers[24].  
 
As the classification of breast cancers becomes more refined, this will lead to more 
sophisticated analysis of differences that will, in turn, inform prognosis and treatment. For 
example, it is becoming more widely acknowledged that triple-negative breast cancers can 
be broadly classified according to the density of lymphocytic infiltrate and that in the future 
this is likely to inform whether patients may be suited to immune-based therapies in 
addition to chemotherapy[25]. In the context of TNBC subtypes[26], TRPC1 expression is 
significantly higher in those with mesenchymal (MES) phenotype[27].  
 
Expression of several calcium pumps and channels is associated with breast cancer-specific 
survival. Such is the case for TRPM7, where high expression is an independent marker of 
progression and metastasis[28]. Another example is TRPV4, which is associated with short 
distant metastasis-free survival[29].  There are also clues that the links between calcium 
signalling and breast cancer diversity extend beyond simple expression differences, since 
ORAI3 is a contributor to store-operated calcium entry (SOCE) in ER-positive but not ER-
negative breast cancer cells[30].  
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2 Key events and processes in breast cancer cells and their intersection with the calcium 
signal 
 
As presented in the now classic reviews by Hanahan and Weinberg[31, 32], there are a 
variety of characteristics that are hallmarks or emerging hallmarks of cancer. A number of 
reviews in the calcium signalling field have discussed in detail how most of these 
characteristics intersect with the calcium signal[33, 34]. Below, we discuss some specific 
examples in breast cancer cells. Table 2 provides a summary of studies that have assessed 
the consequences of silencing calcium channels, pumps and regulators in breast cancer cells 
on the key processes covered in this section (proliferation, migration and invasion, and cell 
death). 
 
2.1 Proliferation 
 
Proliferation has been the major focus of studies defining the consequences of modifying 
the calcium signal in breast cancer cells. The study of the TRP calcium channels in breast 
cancer cell proliferation particularly appears to be expanding. Indeed, the inclusion of breast 
cancers as one of the solid tumours assessed for the consequences of the TRPV6 inhibitor 
SOR-C13[35] reflects the in vitro and in vivo studies where TRPV6 silencing causes a 
reduction in breast cancer cell proliferation[36]. TRPM7 silencing also supresses breast 
cancer cell line proliferation in vitro[37], however, the ability of this channel to function as 
both a Ca2+ and Mg2+ permeable channel and a kinase makes it difficult to determine if this 
effect is solely mediated through Ca2+ signalling. Indirect evidence suggests that the 
antiproliferative effect of TRPM7 silencing is unlikely to be due to the TRPM7 kinase 
domain, since the TRPM7 kinase inhibitor TG100-115 has little effect on MDA-MB-231 
breast cancer proliferation, despite inhibiting migration[38].  
 
ORAI isoforms 1 and 3 play distinct roles in different breast cancer subtypes, with ORAI1 
being more closely associated with the basal molecular subtype and ORAI3 associated with 
ER positive breast cancer cells[30, 39]. However, ORAI1 still regulates store-operated Ca2+ 
entry in ER positive breast cancer cell lines such as MCF-7 cells[39]. Furthermore, ORAI1 
silencing reduces the proliferation of MCF-7 cells in culture, in soft agar and in vivo[40]. 
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ORAI3 silencing also reduces the proliferation of MCF-7 breast cancer cells by invoking cell 
cycle arrest in G1 accompanied by a decrease in cyclin-dependent kinases 4/2, ERK 
phosphorylation and an elevation in the tumour-suppressor p53[41, 42]. ORAI3 silencing 
also reduces MCF-7 breast cancer cells’ anchorage-independent growth and xenograft 
development in vivo[43].  
 
The IP3 activated Ca2+ release channels of the endoplasmic reticulum, also known as IP3 
receptors (IP3Rs), are obvious regulators of breast cancer cell proliferation. Pro-proliferative 
signals often act via G protein-coupled receptors (GPCRs) or tyrosine kinase receptors 
(coupled to the IP3 generating enzyme phospholipase C (PLC)). The potential association 
between IP3Rs and breast cancer growth may not be restricted to the classical GPCR and 
tyrosine kinase receptor activators, as exemplified by the ability of IP3R3 silencing to 
attenuate 17β-oestradiol activated proliferation in MCF-7 breast cancer cells[44]. IP3R3 
silencing inhibits MCF-7 proliferation via cell cycle arrest at the G0/G1 phase, which is 
associated with a decrease in cyclin-D1 and cyclin-dependent kinase 4[45].  
 
The contribution of isoforms of the plasma membrane calcium efflux pump in breast cancer 
cell proliferation seems to be quite different. For example, PMCA2 does not play a major 
role in global cytosolic Ca2+ regulation compared with its related and more ubiquitously 
expressed isoform PMCA1 in MDA-MB-231 breast cancer cells[46, 47], yet PMCA2 silencing 
reduces the proliferation of MDA-MB-231 breast cancer cells and enhances the 
antiproliferative effects of the chemotherapeutic agent doxorubicin[47]. PMCA2 may be 
particularly important in the growth of HER2 positive breast cancers, since when crossed 
with a mouse model of HER2 cancer (MMTV-Neu), PMCA2 null mice develop less 
tumours[22].  
 
The secretory pathway Ca2+ pumps SPCA1 and SPCA2 have both been studied in the context 
of breast cancer proliferation. SPCA1 silencing in MDA-MB-231 breast cancer cells reduces 
proliferation[48]. Mechanistically, silencing of SPCA1 will likely affect many Ca2+ sensitive 
enzymes in the Golgi, such as inhibition of proprotein convertases. This inhibition means 
that some growth factor receptors such as pro-IGF1R are not converted to their active 
forms[48]. SPCA2 silencing in MCF-7 cells reduces proliferation in 2D culture, in soft agar 
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and in vivo[40]. SPCA2 can also be a driver of enhanced proliferation as the overexpression 
of SPCA2 in a non-tumorigenic breast cell line (MCF10A), promotes proliferation and growth 
in soft agar[40]. The pro-proliferative effects of SPCA2 on breast cancer cells is in part due to 
SPCA2-induced activation of ORAI1-mediated Ca2+ influx[40]. Unknown, however, is 
whether SPCA2 may also exhibit some of its effects on proliferation through the regulation 
of the activity of Ca2+ and/or Mn2+ dependent enzymes residing in the Golgi. For MCU, 
elevated levels are associated with more advanced disease in clinical samples, and MCU 
silencing greatly reduces the size of the primary tumour in MDA-MB-231 xenografts. 
However, this effect may be context dependent, and depend on the presence of 
microenvironmental factors[24], because despite effects on in vivo growth, MCU silencing 
has very little or no effect on the proliferation of breast cancer cells in vitro[24]. 
 
2.2 Invasion and Metastasis  
 
Several TRP channels affect breast cancer metastasis and invasion. TRPV4 knockdown in a 
syngeneic 4T1 mouse model greatly reduces the number of metastasis, likely through 
effects on cell rigidity[29], AKT activation and E-cadherin remodelling[49]. TRPV6 silencing 
attenuates the migration and invasiveness of MDA-MB-231 cells in vitro[50] and TRPM7 
knockdown reduces metastasis in a MDA-MB-231 xenograft model[28]. Other calcium 
toolkit members to affect metastasis include ORAI1 and STIM1, the silencing of which, along 
with the non-selective SOCE blocker SKF96365, reduce the metastatic potential of MDA-MB-
231 breast cancer cells in vivo[51]. Studies have subsequently reported the ability of ORAI1 
silencing to supress the motility of breast cancer cells[52-54]. However, recently SOCE 
inhibitors YM58483 and Synta66 were shown to have slightly different effects on the 
migration of MDA-MB-468 breast cancer cells in vitro[55], so further study is still required.    
 
While there have not been many studies of TPC channels in breast cancer metastasis, TPC2 
silencing in the 4T1 mouse syngeneic metastatic mammary cancer model did reduce 
detectable lung metastases in vivo[56]. Using a bladder cancer cell line model, it was 
apparent that TPC2 silencing interferes with the trafficking of β1-integrin and subsequently 
the ability to form the leading edges required for effective cancer cell migration[56]. TPC1 
silencing had similar effects to TPC2 silencing in vitro in this study[56], but the effects of 
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TPC1 silencing on metastasis in vivo were not evaluated[56]. Such assessment is warranted 
given the differential effects of TPC1 and TPC2 silencing in MDA-MB-468 breast cancer 
cells[57].  
 
Despite their relatively recent identification, both PIEZO1 and PIEZO2 have been studied in 
breast cancer cell metastasis. In addition to reports of a functional PIEZO1 channel being 
capable of mechanosensing in MCF-7 breast cancer cells, pharmacological inhibition of 
mechanosensitive channels with GsMTx-4 reduces MCF-7 breast cancer cell migration[58]. 
Given that multiple mechanosensitive pathways are inhibited by GsMTx-4, the 
consequences of PIEZO1 silencing on the migration of a panel of breast cancer cell lines and 
the effects on metastasis in vivo would represent an exciting progression of this emerging 
area. In contrast, the contribution of PIEZO2 to metastasis processes is clearer. MDA-MB-
231-BrM2 is a breast cancer cell line variant with an increased propensity for brain 
metastasis and has higher levels of PIEZO2 than the less brain metastatic parental line[59]. 
With PIEZO2 silencing, these cells have a reduced ability to perform functions that may be 
important in metastasis to the brain, due to an impaired ability to invade and survive in 
confined environments[59].  
 
In the context of intracellular organelles, IP3R3 silencing may exert its anti-migratory effects 
on breast cancer cells by altering the nature of Ca2+ oscillations induced by migratory stimuli 
studies[60] and changes in cellular adhesion processes[60]. In MDA-MB-231 breast cancer 
cells, MCU silencing reduces migration capacity[61] and the ability to invade a collagen 
matrix[24]. MCU silencing also greatly impairs the ability of MDA-MB-231 to metastasise to 
other sites in vivo[24]. Further studies are required in other breast cancer cell lines to 
determine if MCU is a ubiquitous contributor to breast cancer metastasis. 
 
2.3 Cell Death  
 
Although as discussed above, Ca2+ signals may promote the proliferation and invasiveness of 
breast cancer cells, a cytoplasmic free Ca2+ change of sufficient magnitude and duration may 
promote the death of breast cancer cells. Perhaps the most direct evidence for the role of 
the calcium signal in cancer cell death and its potential clinical application is seen using 
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calcium electroporation. The process involves the application of short high voltage electrical 
pulses to cancer affected regions in the presence of high extracellular Ca2+ to induce cancer 
cell necrosis[62]. The recent successful clinical trial in cutaneous metastases from breast 
cancers highlights the great potential of this method[63]. Some cancer cell lines are 
particularly sensitive to calcium electroporation, perhaps through a remodelling of Ca2+ 
signalling, such as reduced capacity for Ca2+ efflux[64]. As will be evident from the studies 
discussed below, the targeting of specific calcium channels to induce the death of breast 
cancer cells is complex and is not always as simple as an induction of cell death via Ca2+ 
overload. 
 
Ca2+ influx mediated by a voltage-gated calcium channel may be important in cell death 
induced by some agents. For example, Cav3.1 silencing reduces apoptosis induced by 
cyclophosphamide in MCF-7 breast cancer cells[65]. Pharmacological activation of some TRP 
channels can induce breast cancer cell death, while other studies report that silencing a 
specific TRP channel can promote cell death. Although at first these may seem 
contradictory, effective Ca2+ homeostasis is essential for cell survival whereas the overload 
of Ca2+ can be a cell death inducer[62, 63].  
 
The ability of pharmacological activation of a TRP channel to promote cell death was first 
demonstrated in prostate cancer cells, where elevated levels of TRPM8 appeared to allow 
TRPM8 pharmacological activation to induce cell death in LNCaP cells[66]. Because of the 
loss of TRPM8 in breast cancer cell lines[67], this was not a viable pathway for assessment in 
breast cancer in vitro or in vivo models. However, studies using inducible overexpression of 
TRPV1 in MCF-7 cells showed that breast cancer cells with high levels of TRPV1 were 
sensitised to cell death induced by the TRPV1 pharmacological activator capsaicin[68]. 
Subsequent identification of TRPV4 overexpression in basal breast cancers and pronounced 
overexpression of TRPV4 in some basal breast cancer cell lines[69], allowed this 
pharmacological response to be explored in breast cancer cells. Activation of TRPV4 with 
GSK1016790A induces cell death via oncosis (at higher concentrations) and apoptosis (at 
lower concentrations) in MDA-MB-468 breast cancer cells, a cell line that expresses high 
levels of TRPV4. TRPV4 silencing reduces the effect and it is absent in breast cancer cell lines 
with lower levels or no TRPV4 expression[69], strongly suggesting that the mechanism of 
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GSK1016790A induced cell death is via TRPV4. Although the TRPV4 activator GSK1016790A  
produces circulatory collapse when given as a rapid IV infusion[70], it has been used in vivo 
where it suppresses the growth of MDA-MB-468 breast cancer cells[69] and improves the 
effectiveness of chemotherapy in a lung cancer in vivo model[71]. Contrastingly, the loss of 
a TRP-mediated Ca2+ influx pathway may also promote cell death. An example is the 
increased apoptotic cell population seen in T47D breast cancer cells with TRPV6 
silencing[36]. Recent studies have added TRPA1 to the TRP family members that are 
important in breast cancer cell death and survival. TRPA1 is overexpressed in some breast 
cancers, and silencing of TRPA1 in HCC1569 breast cancer cells reduces their ability to 
survive H2O2 treatment[72]. This occurs through a TRPA1-mediated Ca2+ influx mechanism 
that promotes reactive oxygen species (ROS) tolerance through an upregulation of anti-
apoptotic and pro-survival pathways[72]. Finally, TRP channels appear to have some link to 
autophagy in breast cancer cells. Silencing of TRPC1 supresses the formation of the 
autophagy marker LC3BII induced by hypoxia in MDA-MB-468 breast cancer cells[27], and 
doxorubicin induction of autophagy in MCF-7 and MDA-MB-231 breast cancer cells is TRPC5 
dependent[73]. 
 
ORAI1 silencing can reverse the anti-apoptotic effects of collagen in MCF-7 and T47D 
cells[74]. The ability of ORAI3 overexpression in T47D cells to protect against cell death 
induced by cell death inducers including thapsigargin, staurosporine, cisplatin, fluorouracil 
(5-FU) and paclitaxel suggests a role for ORAI3 in cell death in some breast cancer cells[75]. 
TPC1 and TPC2 have not yet been extensively assessed in breast cancer. However, a very 
recent study has shown that induced TPC2 overexpression in 4T1 mouse mammary cancer 
cells leads to the accumulation of autophagosomes[76]. There has been a study assessing 
double silencing of IP3R1 and IP3R3 in breast cancer cells. Silencing of these two IP3R 
isoforms is cytotoxic to MCF-7, T47D, HS578T breast cancer cell lines but not to the non-
tumorigenic MCF10A breast cell line[77]. This may be related to the increased sensitivity of 
tumorigenic breast cell lines to undergo death in response to induction of a pathway 
important in autophagy in many cell types, since silencing of IP3R1 and IP3R3 induces the 
autophagy marker LC3-II in all of these cell lines including the non-tumorigenic MCF10A 
breast cell line[77].  
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SERCA pumps clearly have a role in maintaining the viability of breast cancer cells. Indeed, 
cell death induction by various SERCA inhibitors in MCF-7 breast cancer cells is directly 
related to reduced endoplasmic reticulum Ca2+ levels and sustained induction of an 
unfolded protein response[78]. An agent referred to as RL71 inhibits SERCA2 activity[79]. 
Although its selectivity over other SERCA isoforms does not appear to have been fully 
evaluated, it can induce excessive autophagic cell death in MDA-MB-468, MDA-MB-231 and 
SUM-1315 triple negative breast cancer cells[80]. RL71 also suppresses tumour growth and 
increases the apoptotic and autophagic population in MDA-MB-231 xenografts[80]. Future 
studies are required to define if there is a precise role for SERCA2 inhibition in the induction 
of these cell death pathways in triple negative breast cancer cells, or if these effects are 
mediated via a general reduced ability to sequester Ca2+ into the endoplasmic reticulum 
and/or other potential effects of this curcumin analogue[79]. 
 
The effects of silencing specific mitochondrial Ca2+ transporters have not been as dramatic 
in breast cancer cell death as first predicted given the link between mitochondrial calcium 
accumulation and apoptotic pathways in a variety of cell types including breast cancer 
cells[81, 82]. High levels of MCU and MICU1 are not required for the survival of MDA-MB-
231 breast cancer cells[83]. However, there may be conditions or stimuli where 
mitochondrial Ca2+ transporters may be important in breast cancer cell death pathways. For 
example, Ca2+ ionophore-mediated caspase independent cell death in MDA-MB-231 breast 
cancer cells is promoted by MCU silencing[23]. This is despite MCU silencing having no 
significant effect on caspase dependent cell death induced by the Bcl2 inhibitor navitoclax in 
the same cell line[23]. More studies of the specific roles of regulators of mitochondrial 
calcium levels under different conditions in different cell death pathways is still required. 
 
Work from a number of different research groups have contributed to our understanding of 
the role of specific PMCA isoforms in breast cancer cell death. Studies have shown the 
obvious connection between PMCA isoforms that control global [Ca2+]CYT levels and 
sensitivity to cell death inducers that act through increases in global [Ca2+]CYT. For example, 
PMCA1 silencing augments both [Ca2+]CYT increases and necrosis induced by ceramide or 
ionomycin in MDA-MB-231 breast cancer cells[46, 84]. Conversely, the overexpression of 
PMCA2 reduces the sensitivity of T47D breast cancer cells to ionomycin mediated 
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apoptosis[85]. In MCF-7, MDA-MB-231, T47D and ZR-75-1 cells, the disruption of the 
interaction between PMCA2 and calcineurin induces cell death[86]. In some cases, the 
contribution of a specific PMCA isoform may be specific for a particular cell death pathway 
and may even be independent of major effects on global [Ca2+]CYT levels. For example, 
PMCA2 and PMCA4 silencing augment the apoptosis inducing effects of the Bcl-2 inhibitor 
navitoclax in MDA-MB-231 cells, despite silencing of these isoforms in this breast cancer cell 
line having very little effect on global [Ca2+]CYT regulation in comparison to PMCA1 
silencing[46, 87]. Plasma membrane Ca2+ pumps are excellent examples of the diverse 
contributions of specific members of the calcium signalling toolkit to processes important in 
breast cancer progression. 
 
2.4 Resistance 
 
Intrinsic and acquired resistance to therapy is a major challenge to the effective treatment 
of breast cancer. The calcium permeable ion channel most extensively studied in the 
context of therapeutic resistance in breast cancer is TRPC5. TRPC5 is an important regulator 
of multi-drug resistance (MDR)-ATPase 1[88, 89]. Elevated level of TRPC5 is a feature of 
MCF-7 breast cancer cell line made resistant to the cytotoxic agent doxorubicin[88]. 
Significantly, circulating extracellular vesicles and breast cancers in patients who have 
received chemotherapy treatment also have elevated TRPC5[89], with higher levels of 
TRPC5 in breast cancers associated with poorer response to therapy[89]. TRPC5 is not 
simply a marker of resistance or MDR-ATPase 1 expression, since TRPC5 silencing in 
doxorubicin resistant MCF-7 cells can suppress MDR-ATPase 1 expression and increase 
doxorubicin sensitivity[88].  
 
In patients, TRPC5 expressing tumour-derived circulating extracellular vesicles are 
hypothesised to transfer to breast cancer cells with low levels of MDR-ATPase 1. 
Subsequently, resistance is bestowed on sensitive breast cancer cells via the activation of 
the Ca2+-dependent transcription factor NFAT, which increases MDR-ATPase 1 
transcription[89] creating a positive feedback loop for the promotion of drug resistance[89]. 
Another TRP channel, TRPC1, when silenced modulates the levels of ABCC3 (another 
transporter important in drug resistance[90]) in MDA-MB-468 breast cancer cells[91]. 
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Understanding these mechanisms may provide new approaches to overcome drug 
resistance. The role of calcium signalling in resistance should continue to be explored in 
different models and it should be examined in the context of different drug efflux pumps 
and Ca2+ channels. As discussed above, overexpression of ORAI3 in T47D breast cancer cells 
reduces their sensitivity to cell death via a number of agents including chemotherapeutic 
agents such as cisplatin, 5-FU and paclitaxel[75]. This and the association between breast 
cancers with higher levels of ORAI3 and reduced response to therapy suggests that ORAI3 
overexpression might be a mechanism important in resistance[75]. However, further studies 
of changes in ORAI3 expression in in vitro models of acquired resistance and the ability of 
ORAI3 silencing to reverse acquired resistance are needed. 
 
The association between resistance to breast cancer therapy and calcium signalling is not 
confined to calcium channels. The endoplasmic reticulum Ca2+ sequestering pump SERCA2b 
is linked to acquired aromatase inhibitor resistance driven by serum- and glucocorticoid-
inducible kinase 3 (SGK3)[92]. Aromatase inhibitors reduce the production of oestrogen and 
hence attenuate oestrogen mediated growth signalling in ER+ breast cancers[93]. SGK3 is 
able to help maintain SERCA2b activity and thus can prevent endoplasmic reticulum stress 
and associated cell death in aromatase inhibitor resistant cells[92].  
 
2.5 Differentiation and stemness 
 
Therapies that can induce cancer cell differentiation include histone deacetylase 
inhibitors[94]. In this context, differentiation of MCF-7 breast cancer cells induced by the 
histone deacetylase inhibitors butyrate, phenylbutyrate and valerate as well as phorbol 12-
myristate 13-acetate (PMA) are associated with a significant increase in the levels of the 
Ca2+ efflux pump PMCA4b[95]. Similarly, sodium butyrate and trichostatin A-mediated 
differentiation of MCF-7 and MDA-MB-231 breast cancer cells produces an upregulation of 
SERCA3[96]. Further evidence that SERCA3 may be dependent on the degree of de-
differentiation is found in studies showing that SERCA3 levels are decreased in early non-
malignant epithelial lesions compared to normal breast acinar epithelial cells[18]. SERCA3 
levels also decrease with increasing breast cancer grade as measured by the Elston-Ellis 
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grading system[97]. Hence, some calcium transporters might be markers of differentiation 
in breast cancer cells. 
 
There are also emerging clues of an association between stemness and calcium signalling. 
Stemness of breast cancer cells may be critical for the establishment of tumours and 
reoccurrence. Stemness is also a feature of epithelial to mesenchymal transition (EMT)[98]. 
Cells at different states on the EMT spectrum can adopt more invasive features and be more 
resistant to therapies[98]. In MDA-MB-468 breast cancer cells, the calcium signal is critical 
to EMT induction via both epidermal growth factor and hypoxia[99]. Silencing and 
pharmacological inhibition of TRPM7 inhibit increases in levels of the mesenchymal marker 
vimentin induced by epidermal growth factor in this model[99]. A connection between EMT 
and changes in calcium signalling and/or the expression of specific calcium channels and 
calcium pumps occurs in other breast cancer cell lines and with other EMT inducers[100-
103]. A link between cancer stem cells and the calcium signal has been reported by Lu and 
colleagues[104]. Carboplatin treatment enriches the cancer stem cell population via the 
calcium store release channel ryanodine receptor 1(RYR1)[104]. When RYR1 is knocked 
down, there is a reduction in tumour initiation and a delay in reoccurrence in an in vivo 
model[104], highlighting the important role of RYR1 in breast cancer stem cell enrichment. 
 
3 Importance of calcium signals in the breast cancer microenvironment  
 
The tumour microenvironment is a milieu of cells, factors and events that can (depending 
on the context) promote or supress tumour progression[105, 106]. Although the importance 
of the tumour microenvironment in the progression of cancer has been known for 
decades[107], studies looking at the involvement and reliance on the calcium signal in the 
tumour microenvironment are in their infancy compared to calcium and its relationship to 
cancer cell proliferation, invasiveness and death. However, as outlined below, many of the 
studies that have been conducted have included breast cancer models or have focused on 
processes with particular significance to breast cancer. 
 
3.1 Angiogenesis 
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The oxygen and nutrient requirements of the growing tumour make the formation of the 
tumour vascular through angiogenesis a key event in tumour progression. A number of 
studies have highlighted the significance of specific calcium permeable ion channels in this 
process. One such example is seen in the proposed potential targeting of TRPV4. Endothelial 
cells derived from the vasculature of breast cancers have higher levels of TRPV4, and TRPV4 
inhibition suppresses the stimulated migration of breast cancer derived endothelial cells, 
suggesting that pharmacological inhibition of TRPV4 could be used to suppress 
angiogenesis[108]. More recently, ORAI1 has been linked to angiogenesis in studies using 
MDA-MB-231 and BT-549 triple negative breast cancer cells[109]. In an immortalised human 
microvascular endothelial cell line of tumour angiogenesis (HMEC-1 cells), the ability of 
conditioned media from MDA-MB-231 and BT-549 breast cancer cells to promote tube 
formation (a measure of angiogenic induction) was significantly reduced when ORAI1 was 
silenced in these breast cancer cell lines[109]. These studies identify a role for ORAI1-
mediated Ca2+ influx in the release of pro-angiogenic factors in triple negative breast cancer 
cells. Hence, the contribution of calcium channels and pumps to tumour angiogenesis may 
involve the modification of processes in endothelial cells of the host or in pro-angiogenetic 
processes emanating from breast cancer cells.  
 
3.2 Immune Cells 
 
The ability of immune cells to contribute to the activation of pro-metastatic pathways and 
the increasing focus of immune based therapies to treat cancers[32] make this an area of 
almost certain growth in the study of calcium signalling in breast cancer. SOCE in immune 
cells is particularly relevant as the field considers the potential of SOCE inhibitors as 
therapies for cancers including those of the breast. Studies of STIM1 and STIM2 double 
knockout mice, which have a complete loss of SOCE, show that the loss of SOCE reduces the 
ability of CD8(+) T cells to control the growth of melanoma and colon cancer cells in 
syngeneic xenografts[110]. Hence, the presence of SOCE is clearly critical for anti-tumour 
immunity[110]. However, more recently, it has been proposed that a partial inhibition of 
ORAI1 may actually promote cytotoxic T lymphocyte and natural killer cell anticancer cell 
activities[111].  
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3.3 Cancer associated fibroblasts and adipocytes  
 
The role of cancer associated fibroblasts in breast cancer progression has been extensively 
reviewed (e.g. [112]). However, despite this and the emergence of studies of calcium 
signalling pathways in the context of cancer associated fibroblasts in other cancer 
types[113-115], there have been no studies assessing the intersection between cancer 
associated fibroblasts and calcium signalling in breast cancer. Likewise, despite the 
association between obesity and breast cancer[116], and the importance of the calcium 
signal in the interplay between adipocytes and ovarian cancer cells[117] there are only a 
limited number of studies of this phenomenon in breast cancer. However, the report that 
the adipocyte-secreted factor resistin can elevate [Ca2+]CYT levels in MDA-MB-231 cells and 
that intracellular Ca2+ chelation can block Src activation by resistin in these cells[118] 
highlight the likely significance of any future work in this area.  
 
4 Conclusion 
Breast cancers are diverse in their histopathological features and gene expression profiles 
and in many cases also in their expression of specific regulators of the calcium signal. 
Calcium signalling plays a key role in processes important in breast cancer cells and these 
span proliferation to invasiveness and apoptosis to multidrug resistance. The recent studies 
defining a role for calcium signalling in many events important in the tumour 
microenvironment highlights this aspect of calcium signalling in breast cancer as one for 
further study. 
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Table 1: Remodelling of calcium channels and pumps in breast cancer. Examples of altered 
levels of calcium permeable ion channels and calcium pumps in breast cancer tissue or cell 
lines compared to controls. Please note that in some cases, differences are more evident in 
specific breast cancer subtypes. 
Calcium channels 
and pumps 
Differential expression in breast cancer 
tissueT / cell lineC compared to normal 
IP3R1 ↔C[119] 
IP3R2 ↑C[119] 
IP3R3 ↑C[119] 
ORAI1 ↑C[39] 
ORAI2 ↔C[39] 
ORAI3 ↑C,T[41, 42], ↔C[39] 
PIEZO1 ↑C[58] 
PMCA1 ↑C[120] 
PMCA2 ↑C[121] 
PMCA4 ↓C[121] 
SERCA3 ↓T[18] 
TPC1 and 2 No trendC[57] 
TRPA1 ↑C,T[72] 
TRPC1 ↑T[50] 
TRPC6 ↑T[50] 
TRPM7 ↑T[50] 
TRPM8 ↑T[50, 122] 
TRPV1 ↑T[122] 
TRPV2 ↓T[122] 
TRPV6 ↑T[36, 50] 
 
↔ similar levels in cancer and normal samples 
↑ increased levels in cancer samples 
↓ decreased levels in cancer samples 
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Table 2: Consequences of silencing/knockdown of calcium channels, pumps and regulators 
in breast cancer cell lines. Please note that some of these consequences may be specific for 
the agent and/or type of breast cancer cell lines (e.g. oestrogen receptor expression status). 
 Channel
/ 
Pump/ 
Regulato
r 
  
 
Outcome of silencing/knockdown 
Effect on 
proliferation 
Effect on 
migration 
pathways,  
invasion or 
metastasis  
Effect on cell death 
VGCC T-type 
(Cav3.1) 
↑[65] - ↓ cyclophosphamide-
induced apoptosis[65] 
TRP TRPA1  - - ↓ survival on H2O2 
treatment[72]  
TRPC1  ↓[123] - ↓ autophagy[27] 
TRPM7  ↓[37] ↓*[28] - 
TRPV4 - ↓*[29] ↓ GSK1016790A-
induced cell death[69]  
TRPV6  ↓[21, 36] ↓[50] ↑[36] 
ORAI & STIM ORAI1  ↓*[40] ↓*[51-54] Reverse antiapoptotic 
effect of collagen[74] 
ORAI3  ↓*[41-43]  - ↑[41] 
STIM1  - ↓*[51, 54] - 
TPC TPC1  ↔[57] - - 
TPC2  ↔[57] ↓*[56] - 
PIEZO PIEZO2  - ↓[59] - 
IP3R  IP3R2   ↑ autophagy[119] 
IP3R3 ↓[44, 45]  ↓[60] ↑ autophagy[119] 
IP3R1 
and 
IP3R3  
- - ↑[77] 
RYR - - - - 
20 
 
PMCA PMCA1  ↔[47] - ↑ cell death induced by 
ceramide/ionomycin[46, 
84] 
PMCA2  ↓[47] - ↑[87] 
PMCA4  ↔[47] - ↑ cell death induced by 
navitoclax[46] 
SPCA SPCA1  ↓[48] - - 
SPCA2  ↓*[40] - - 
Mitochondrial 
Ca2+ regulators 
MCU  ↓ size of 
primary 
tumour in 
xenograft*[24] 
 
↔ in vitro[24] 
↓*[24] ↔[83] /  
↑ Ca2+ ionophore-
mediated caspase 
independent cell death, 
↔ for navitoclax 
induced death[23]   
MICU1  - - ↔[83] 
- for not assessed 
↔ for no change 
↓ decreased  
↑ increased  
* included in vivo data 
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Figure legends 
Figure 1: Specific examples on calcium pumps, channels and exchangers contributing to 
calcium signalling in breast cancer cells. Plasmalemmal Ca2+ permeable ion channels 
include those with apparent constitutive activity (TRPV6), those activated by external stimuli 
(TRPV4) or the depletion of intracellular Ca2+ stores (ORAI1). Ca2+ pumps include plasma 
membrane calcium efflux pumps such as PMCA2, endoplasmic reticulum Ca2+ sequestration 
pumps such as SERCA3 and secretory pathway calcium pumps that also transport 
manganese ions such as SPCA2[6, 124]. Other key members of the proteins which can 
control the calcium signal include intracellular Ca2+ store channels activated by G-protein 
coupled receptor-mediated production of IP3 such as IP3R3 and components of 
mitochondrial calcium regulation such as MCU[6, 125]. 
 
Figure 2: Diversity of breast cancer: clinical diagnostic classification and overlapping 
phenotypic features. Histologic grade generally reflects the overall level of differentiation, 
assessed according to the mitotic index of a tumour, degree of nuclear pleomorphism and 
extent of normal mammary tubule formation, with higher grade indicating a more primitive 
state associated with poorer clinical outcomes. Breast cancer clinical diagnosis also involves 
assessment of HER2 and hormone receptors, which qualifies patients for HER2-targeted and 
anti-oestrogen therapies, respectively. Triple-negative breast cancer (TNBC) is standardly 
treated with cytotoxic chemotherapy. Gene expression profiling of large, cross-sectional 
breast tumour cohorts has revealed six intrinsic molecular subtypes. Their prevalence 
amongst the clinical diagnostic groups is indicated with pie charts. Gene expression profiling 
of TNBC cohorts has revealed a phenotype broadly similar to basal/myoepithelial cells of the 
normal breast, further stratified according to whether they express mesenchymal and stem 
cell markers (claudin-low and MES groups), and also according to the density of tumour-
infiltrating lymphocytes, reflected by the transcriptomic profile of tissue samples. Basal-like, 
immune-activated (BLIA) tumours are more likely to respond to chemotherapy than basal-
like, immune suppressed (BLIS) tumours. The significance of the normal-like molecular 
subgroup remains unclear. This figure was generated using publicly available data from the 
Molecular Taxonomy of Breast Cancer International Consortium (Metabric; [126]) and TNBC 
profiling analysis by Burstein and colleagues[26].  
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